Drug Trial Radar · NCT07090655
A Phase 1 Study of Budoprutug (TNT119) Subcutaneous and Intravenous Injections in Normal Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 11, 2025
Primary completion
Apr 7, 2026
Study completion Apr 7, 2026
Sponsor
- Lead sponsor
- Climb Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective is to assess the safety and tolerability of subcutaneous and intravenous injection forms of budoprutug in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
BudoprutugDrug
Subcutaneous or IV administration
PlaceboDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of Single Ascending Doses of budoprutug in Healthy ParticipantsTime frame: Day 57
- Incidence of infusion-related reactions (IRRs) for IV administrationTime frame: Day 57
- Incidence of injection site reactions (ISRs) for SC administrationTime frame: Day 57
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Brisbane
Brisbane, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.